Trivarx (ASX:TRI) — Material Events
ASX:TRI · 12 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
TrivarX faces funding test as Stabl-Im pivot deepens FY2026 lossHigh
TrivarX shifts focus to Stabl-Im MRI platform after $8.76m FY2026 loss and going concern warning
29 Sept 2026
·Annual Report
·88
TrivarX Secures Stabl-Im IP, Validates Mental Health Diagnostic in US Veteran TrialMedium
TrivarX advances neuro-oncology imaging with Stabl-Im acquisition and reports strong US veteran mental health trial results
30 Jan 2026
·Quarterly Activities Report
·85
TrivarX Advances Brain Tumour Detection with Stabl-Im Acquisition MoveMedium
TrivarX moves to acquire innovative brain tumour imaging technology Stabl-Im, pending shareholder approval
5 Nov 2025
·Option Exercise and Acquisition Announcement
·85
TrivarX Names Dr Danielle Meyrick CEO to Lead Stabl-Im Brain Cancer Imaging TrialsMedium
TrivarX appoints Dr Danielle Meyrick as CEO to advance Stabl-Im brain cancer imaging platform into clinical trials
29 Apr 2026
·Executive Appointment
·85
TrivarX Advances US Veteran Mental Health Trial, Eyes Brain Tumor Imaging ExpansionHigh
TrivarX advances US mental health trial with strong interim results and moves to acquire novel brain tumor imaging tech
31 Oct 2025
·Quarterly Activities Report and Appendix 4C
·85
TrivarX’s Single-Lead ECG Algorithm Detects Depression with 97% Sensitivity in VeteransMedium
TrivarX's single-lead ECG algorithm shows high accuracy detecting depression in US veterans
18 Dec 2025
·Clinical Trial Results
·85
TrivarX Advances Stabl-Im Brain Imaging Toward Phase 1 Trials with New CEO AppointmentMedium
TrivarX advances Stabl-Im to Phase 1 trials, appoints new CEO, maintains strong cash position
30 Apr 2026
·Quarterly Activities Report
·80
TrivarX Secures $3.5M to Propel Stabl-Im Brain Tumour Imaging into Clinical TrialsMedium
TrivarX secures $3.5M funding to advance Stabl-Im brain tumor imaging into clinical trials
22 Dec 2025
·Capital Raising
·80
TrivarX Advances Neuro-Oncology with $4.2M Raise and Stabl-Im AcquisitionMedium
TrivarX posts $1.26M half-year loss, acquires Stabl-Im IP, validates mental health screening tech, raises $4.2M
24 Feb 2026
·Appendix 4D Half-Year Financial Report
·75
TrivarX Sets Q1 2027 Target for First Stabl-Im ParticipantMedium
TrivarX advances Stabl-Im toward planned clinical feasibility study
23 Sept 2026
·Clinical Development Update
·70
TrivarX Engages CRO Beyond to Advance Stabl-Im Phase 1 TrialMedium
TrivarX engages CRO Beyond Drug Development to progress Stabl-Im Phase 1 safety trial
22 May 2026
·Clinical Trial Progress Update
·70
TrivarX Secures Key Supply for Stabl-Im Phase 1 Trial LaunchMedium
TrivarX secures product supply for Phase 1 Stabl-Im clinical trial in 2026
16 July 2026
·Clinical Trial Update
·70
No articles in this tier for the last 12 months.
Market Mentions
6
- appeared in market wrap coverage
These are market wrap articles where Trivarx (ASX:TRI) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 40 (28 Sept -> 2 Oct) 2026
3 Oct 2026
Healthcare Wrap - Week 29 (13 July -> 17 July) 2026
18 July 2026
Healthcare Wrap - Week 21 (18 May -> 22 May) 2026
23 May 2026
Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026
2 May 2026
Healthcare Wrap - Week 9 (23 Feb -> 27 Feb) 2026
28 Feb 2026